Company profile: Zap Surgical
1.1 - Company Overview
Company description
- Provider of the ZAP-X gyroscopic radiosurgery platform for treating brain tumors, lesions, and head and neck conditions, utilizing a modern linear accelerator that eliminates radioactive source replacements. Offers vault-free design to reduce infrastructure costs, dual independent gantries for >1000 non-coplanar beam angles, tungsten-shielded collimation, and SRS webinars and clinical publications.
Products and services
- ZAP-X Gyroscopic Radiosurgery platform: Medical-grade gyroscopic radiosurgery system utilizing a modern linear accelerator to treat brain tumors, lesions, and head-and-neck conditions while eliminating routine radioactive source replacements
- Dual independent gantries: Multi-axis dual independent gantries deliver over 1,000 unique non-coplanar beam angles to optimize dose fall-off and conformality during cranial radiosurgery treatments
- Vault-free design: Facility-scale vault-free design eliminates shielded radiation bunker construction, significantly reducing infrastructure expenditures associated with installing radiosurgery systems
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Zap Surgical
Accession Therapeutics
HQ: United Kingdom
Website
- Description: Provider of immuno-oncology therapeutics based on Trocept, a stealth virus platform engineered to selectively enter cancer cells while bypassing healthy cells to deliver broad, potent payloads and minimize systemic toxicity, targeting hard-to-treat cancers. Pipeline includes TROCEPT-01 (immune checkpoint inhibitor), TROCEPT-02 (universal bispecific immune activator), and other targeted programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Accession Therapeutics company profile →
Arius Research
HQ: Canada
Website
- Description: Provider of biotechnology solutions centered on the discovery and development of antibody therapeutics, primarily targeting breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma, leveraging its FunctionFIRST platform to identify monoclonal antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arius Research company profile →
DYSIS Medical
HQ: United Kingdom
Website
- Description: Provider of medical imaging systems for the non-invasive, in-vivo detection of cancerous and pre-cancerous lesions, including the DYSIS Colposcope for imaging the cervix and lower genital tract with adjunctive acetowhitening display; DYSISmap to quantify acetowhitening and overlay a color-coded map to assist biopsy targeting; and DYSIS SMARTtrack for enhanced documentation with high-resolution images, video, and instant exam playback.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DYSIS Medical company profile →
Valerio Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology therapeutics leveraging the platON chemistry platform to generate DNA-decoy compounds targeting intracellular DNA-binding proteins for tumors and inflammatory diseases; develops AsiDNA and VIO-01 to disrupt DNA repair and activate the STING pathway, and Belinostat/Beleodaq, a histone deacetylase inhibitor for hematological and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valerio Therapeutics company profile →
Oncoscope
HQ: United States
Website
- Description: Provider of optical biopsy and imaging systems for epithelial tissues in the oral cavity, esophagus, stomach, colon, lung, cervix, and bladder, delivering in vivo measurements of cell nuclei diameter and density to help physicians identify pre-cancerous tissues for biopsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncoscope company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Zap Surgical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Zap Surgical
2.2 - Growth funds investing in similar companies to Zap Surgical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Zap Surgical
4.2 - Public trading comparable groups for Zap Surgical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →